Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 14/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944061 | 0.91 | PIM1 (0.54) | FYNPIM1KCNH2F2RL3PIM2 | |
| SCHEMBL625292 | 0.91 | PIM1 (0.53) | PIM1KCNH2F2RL3PIM2FLT3 | |
| SCHEMBL626259 | 0.91 | PIM1 (0.53) | PIM1KCNH2F2RL3PIM2FLT3 | |
| SCHEMBL623435 | 0.90 | PIM1 (0.46) | PIM1KCNH2F2RL3PIM2FLT3 | |
| Hydrochloric Acid SCHEMBL625023 | 0.90 | PIM1 (0.45) | PIM1KCNH2F2RL3PIM2FLT3 | |
| SCHEMBL1945224 | 0.85 | F2RL3 (0.57) | FYNPIM1KCNH2F2RL3PIM2 | |
| SCHEMBL625501 | 0.84 | PIM1 (0.43) | PIM1KCNH2F2RL3PIM2FLT3 | |
| SCHEMBL623873 | 0.84 | IDH1 (0.44) | PIM1KCNH2MAPTTHRB | |
| SCHEMBL1944243 | 0.84 | FYN (0.62) | FYNF2RL3MAPTTHRBRXFP1 | |
| SCHEMBL625561 | 0.83 | PIM1 (0.49) | PIM1KCNH2F2RL3PIM2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885PIM1 72/4885KCNH2 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.